ZNF267 and hepatocellular carcinoma: Whilst ZNF267 behaves as an oncogene in hepatocellular carcinoma, in acute lymphoblastic leukaemia, and in diffuse large B-cell lymphoma, in which its expression also predicts poor survival [75,76,77], this study found that ZNF267 amplification is associated with the disease stage but not with progression-free survival.